Skip to content
Menu

CollPlant Biotechnologies Ltd CLGN

Full chart Compare
Set alert

Price alert · CLGN

All alert types
4.64 USD +0.68 (+17.17%)

Regular-session close

4.80 +0.16 +3.45%

After hours · Nov 12, 4:00 PM ET

4.05 Day range 4.64
2.64 52-week range 22.50
YTD
0.00%
1 year
0.00%

 

No chart data for this range yet.
Market cap
14.27M
Revenue (ttm)
689.00K
EPS (ttm)
-9.33
Shares out
11.45M
Forward P/E
-8.82
YTD return
0.00%
1-year return
0.00%
50-day average
4.04
Volume
125.27K
Avg volume
384.96K
Open
4.05
Previous close
3.96
Day's range
4.05 – 4.64
52-week range
2.64 – 22.50
Beta
0.48
Price target
12.50 (+169.4%)

Key statistics

200-day average
4.90
Enterprise value
33.32M
Price / sales
57.19
Price / book
1.39
Revenue growth
-97.60%
Free cash flow
2.13M
Total cash
18.92M
Total debt
3.38M
Return on equity
-61.55%
Short % of float
0.15%

Fundamental scorecard

4 of 25 checks passed on CLGN’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend No data

Statements to Jun 30, 2026.

Financials — quick view

All financials
CLGN Revenue — quarterly 108.00K
CLGN Net income — quarterly -2.73M
CLGN EPS — quarterly -1.89

Earnings

CLGN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 27, 2024Sep 1, 2024-0.37-0.38-0.01-2.70%
Aug 20, 2024Jun 1, 2024-0.35-0.37-0.02-5.71%
Aug 20, 2024Jun 1, 2024-0.35———
May 29, 2024Mar 1, 2024-0.35-0.37-0.02-5.71%
May 29, 2024Mar 1, 2024-0.35———
Apr 4, 2024Dec 1, 20230.00-0.42——

Upgrades / downgrades

CLGN analyst upgrades and downgrades
DateFirmActionFromTo
Nov 29, 2024HC Wainwright & Co.reitBuyBuy
Nov 27, 2024D. Boral CapitalmainBuyBuy
Aug 21, 2024HC Wainwright & Co.reitBuyBuy
Aug 20, 2024EF HuttonmainBuyBuy
Aug 5, 2024EF Huttoninit—Buy
May 30, 2024HC Wainwright & Co.reitBuyBuy

About CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

Sector
Healthcare
Industry
Biotechnology
Country
Israel

News

Your note

Sign in to keep a note on CLGN — it syncs with the Stock Master app.

Institution ownership

CLGN institution ownership
Holder% heldSharesValueReported
Villere St. Denis J. & Co. LLC4.33%484,8671.67MSep 29, 2024
Pinnacle Associates, Ltd.4.18%468,1091.61MSep 29, 2024
Brown Advisory Inc.1.07%119,465410.96KSep 29, 2024
AMH Equity Ltd.0.89%99,205341.26KSep 29, 2024
Benjamin Edwards, Inc.0.21%23,81081.91KSep 29, 2024
Pathstone Holdings, LLC0.15%17,00058.48KSep 29, 2024

Fund ownership

CLGN fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.05%5,92520.38KOct 30, 2024